An interventional study of Estradiol cream 0.01% and Cetaphil in Prepubertal Labial Adhesions, sponsored by Children's Mercy Hospital Kansas City. Completed at 1 site in United States. Open to female participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2025-04-23.
Sponsored by Children's Mercy Hospital Kansas City · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Vulvar Diseases with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Vulvar Diseases · United States.
Among the 13 studies in Vulvar Diseases with a site in United States, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2014, is one of 5 with no phase, and was the 3rd registered.
21 studies on the registry are indexed under Vulvar Diseases; 6 are open to participants now.
Browse Vulvar Diseases studies →4 of the 13 studies in Vulvar Diseases with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
University of Virginia · Sites in United States
Ages 18+ · Women only
Frantz Viral Therapeutics, LLC · Sites in United States
Ages 18+ · Women only
Marengo Therapeutics, Inc. · Sites in United States, Canada, France and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Vulvar Diseases studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 3 Months to 12 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5
First in 1995; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 64 across 17 interventional studies indexed under Vulvar Diseases.
Median enrollment 61 across the 11 interventional studies, 860 across the 2 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 10 most frequent:
Children's Mercy Hospital Kansas City is the lead sponsor of 210 studies on the registry; 20 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
Children's Mercy Hospital Kansas City has 1 study filed under Vulvar Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Vulvar Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
| NCT06075264Frantz Viral Therapeutics, LLCPhase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3) | 2026-12 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Vulvar Diseases with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
First-line treatment for labial adhesions in prepubertal girls has been topical estrogen. This study aims to evaluate an alternative and less costly option of treatment with potentially less side effects.
Primary Hypothesis:
There will be a difference in complete resolution of labial adhesions with topical estrogen with lateral traction as compared to an emollient with lateral traction.
The etiology of labial adhesions is unclear but appears to be related to hypoestrogenism in combination with vulvar irritation. For many years, first-line treatment for labial adhesions in prepubertal girls has been topical estrogen. With the use of topical estrogen, 50% of labial adhesions resolve in 2 to 3 weeks and most labial adhesions resolve with 6 weeks of treatment. However, because topical estrogen is systemically absorbed, its use is associated with side effects such as breast budding, vulvar hyperpigmentation, vaginal bleeding. There is a high risk of recurrence of labial adhesions of up to 35% after treatment with topical estrogen. In addition, topical estrogen is costly. Therefore, there continues to be controversy over the optimal treatment of labial adhesions in prepubertal girls.
Generally, for medical treatment of labial adhesions, topical estrogen is applied to the adhesion whist applying gentle lateral traction to promote separation of the labia. It is, therefore, plausible that the lateral traction applied to the adhesion site is what ultimately results in the separation of the labial fusion, while the use of estrogen improves healing after mechanical separation.
This is a single site, prospective, randomized, double-blinded study evaluating the comparative effectiveness of topical estrogen with lateral traction versus topical emollient with lateral traction for the treatment of labial adhesions in prepubertal girls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Drug: Cetaphil
Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Drug: Estradiol cream 0.01%
Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Also known as: Estrace Vaginal
Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Complete Resolution of Labial Adhesion.
The first assessment will be 3 weeks after initiation of treatment. The final assessment will be 6 weeks after initiation of treatment.
Time frame: 3 weeks and 6 weeks
Composite Severity Scale of Labial Adhesion Over Time
Response to treatment of labial adhesion is dependent not only upon the size of the adhesion but also the thickness. A more accurate measurement of response to treatment would, therefore, incorporate both measurements. For this study, the percentage of closure of the introitus at presentation was assigned an ordinal value as follows: 1=25%, 2=50%, 3=75%, and 4=100%. The degree of thickness of the labial adhesion was also measured in a similar fashion: 1=thin, 2=intermediate and 3= thick. Those that were resolved received a rating of 0 on both scales. A composite severity scale was created by multiplying the value assigned to the percentage of introital closure by that assigned to the thickness of the adhesion for each of the 3 study visits. The composite severity scale ranged from 0 to 12. This allowed a comparison of treatment effect between each group over time wherein a lower composite severity score corresponded to a less severe labial adhesion.
Time frame: 3 weeks and 6 weeks
| Milestone | Cetaphil | Estradiol Cream 0.01% |
|---|---|---|
| Started | 21 | 22 |
| Completed | 18 | 19 |
| Not completed | 3 | 3 |
The first assessment will be 3 weeks after initiation of treatment. The final assessment will be 6 weeks after initiation of treatment.
| Participants | Cetaphil | Estradiol Cream 0.01% |
|---|---|---|
| Complete Resolution of Labial Adhesion. | 21 | 22 |
Response to treatment of labial adhesion is dependent not only upon the size of the adhesion but also the thickness. A more accurate measurement of response to treatment would, therefore, incorporate both measurements. For this study, the percentage of closure of the introitus at presentation was assigned an ordinal value as follows: 1=25%, 2=50%, 3=75%, and 4=100%. The degree of thickness of the labial adhesion was also measured in a similar fashion: 1=thin, 2=intermediate and 3= thick. Those that were resolved received a rating of 0 on both scales. A composite severity scale was created by multiplying the value assigned to the percentage of introital closure by that assigned to the thickness of the adhesion for each of the 3 study visits. The composite severity scale ranged from 0 to 12. This allowed a comparison of treatment effect between each group over time wherein a lower composite severity score corresponded to a less severe labial adhesion.
| units on a scale | Cetaphil | Estradiol Cream 0.01% |
|---|---|---|
| Baseline | 6.3 ± 3.1 | 6.2 ± 2.0 |
| 3 weeks | 2.3 ± 2.4 | 1.5 ± 1.7 |
| 6 weeks | 1.9 ± 2.1 | 1.6 ± 1.9 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetaphil | — | 0/21 (0%) | 1/21 (4.8%) |
| Estradiol Cream 0.01% | — | 0/22 (0%) | 1/22 (4.5%) |
| Event | Cetaphil | Estradiol Cream 0.01% |
|---|---|---|
| Vulvar irritationSkin and subcutaneous tissue disorders | 1/21 | 1/22 |
| Age, Continuous(months) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| Mean | 33 (5 to 84) | 26 (4 to 108) | 29 (4 to 108) |
| Sex: Female, Male(Participants) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| Female | 21 | 22 | 43 |
| Male | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| United States | 21 | 22 | 43 |
| % introital closure(participants) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| 25% | 1 | 0 | 1 |
| 50% | 5 | 4 | 9 |
| 75% | 4 | 7 | 11 |
| 100% | 11 | 11 | 22 |
| Thickness of labial adhesion(Participants) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| Thin | 5 | 4 | 9 |
| Intermediate | 14 | 17 | 31 |
| Thick | 2 | 1 | 3 |
| Urinary tract infection(Participants) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| Present | 0 | 2 | 2 |
| Absent | 21 | 20 | 41 |
| Vulvovaginitis(Participants) | Cetaphil | Estradiol Cream 0.01% | Total |
|---|---|---|---|
| Present | 0 | 0 | 0 |
| Absent | 21 | 22 | 43 |
2 further baseline measures are reported on the registry.
The record gives a start of Sep 2014, a primary completion of May 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2019, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion
Children's Mercy Hospital Kansas City →